Show simple item record

dc.contributor.authorMagnifico, Irene
dc.contributor.authorPetronio, Giulio Petronio
dc.contributor.authorVenditti, Noemi
dc.contributor.authorCutuli, Marco Alfio
dc.contributor.authorPietrangelo, Laura
dc.contributor.authorVergalito, Franca
dc.contributor.authorMangano, Katia
dc.contributor.authorZella, Davide
dc.contributor.authorDi Marco, Roberto
dc.date.accessioned2020-11-30T18:28:29Z
dc.date.available2020-11-30T18:28:29Z
dc.date.issued2020-11-01
dc.identifier.urihttp://hdl.handle.net/10713/14150
dc.description.abstractAtopic dermatitis (AD) is a pathological skin condition with complex aetiological mechanisms that are difficult to fully understand. Scientific evidence suggests that of all the causes, the impairment of the skin barrier and cutaneous dysbiosis together with immunological dysfunction can be considered as the two main factors involved in this pathological skin condition. The loss of the skin barrier function is often linked to dysbiosis and immunological dysfunction, with an imbalance in the ratio between the pathogen Staphylococcus aureus and/or other microorganisms residing in the skin. The bibliographic research was conducted on PubMed, using the following keywords: ‘atopic dermatitis’, ‘bacterial therapy’, ‘drug delivery system’ and ‘alternative therapy’. The main studies concerning microbial therapy, such as the use of bacteria and/or part thereof with microbiota transplantation, and drug delivery systems to recover skin barrier function have been summarized. The studies examined show great potential in the development of effective therapeutic strategies for AD and AD-like symptoms. Despite this promise, however, future investigative efforts should focus both on the replication of some of these studies on a larger scale, with clinical and demographic characteristics that reflect the general AD population, and on the process of standardisation, in order to produce reliable data.en_US
dc.description.urihttps://doi.org/10.3390/ph13110411en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofPharmaceuticalsen_US
dc.subjectAtopic dermatitisen_US
dc.subjectCutaneous dysbiosisen_US
dc.subjectDrug delivery systemsen_US
dc.subjectMicrobial therapyen_US
dc.subjectSkin barrieren_US
dc.subjectStaphylococcus aureusen_US
dc.titleAtopic dermatitis as a multifactorial skin disorder. Can the analysis of pathophysiological targets represent the winning therapeutic strategy?en_US
dc.typeArticleen_US
dc.identifier.doi10.3390/ph13110411
dc.source.volume13
dc.source.issue11
dc.source.beginpage1
dc.source.endpage18


This item appears in the following Collection(s)

Show simple item record